Introduction {#section1-2374373517732384}
============

Medication nonadherence is an established therapeutic challenge and a dilemma to both the patients and the health-care providers. It contributes to a reduction in the patients' quality of life and increases both the individual's and nations' health-care expenditures ([@bibr1-2374373517732384],[@bibr2-2374373517732384]). The multifactorial nature of medication nonadherence makes proffering an effective solution a challenge. Many factors such as patients' forgetfulness, medication side effects, health system structure, social support, and health-care providers' attitude and skills have been documented to influence patients' medication adherence ([@bibr3-2374373517732384] [@bibr4-2374373517732384] [@bibr5-2374373517732384]--[@bibr6-2374373517732384]). A high cost of drugs and high patients' out-of-pocket drug cost payment have been consistently linked with medication nonadherence in many disease conditions ([@bibr7-2374373517732384]). The influence of drug cost on MA is indeed vital in a country such as Nigeria, where it is established that the drug cost accounts for more than two-thirds of the costs of treating chronic diseases ([@bibr8-2374373517732384]). The National Health Insurance Scheme (NHIS) was thus proffered by many stakeholders in health care including the World Health Organization as a solution to improving patients' accessibility to drugs and health-care services ([@bibr7-2374373517732384]).

Evidence has since shown that the NHIS improves health-care accessibility and reduces catastrophic spending on drugs in many health-care settings ([@bibr9-2374373517732384],[@bibr10-2374373517732384]). This increase in health-care access can however not be assumed to have improved the health care of the population. For instance, a study in Quebec showed that having a health insurance cover with a small co-payment did not contribute to a reduction in death, heart failure, and angina among patients with chronic diseases ([@bibr11-2374373517732384]). Nigeria, a middle-income nation, commenced the implementation of the NHIS more than a decade ago. The scheme presently covers about 8% of the estimated 170 million of the country's population, mainly those in the formal sectors of the economy ([@bibr12-2374373517732384]). The premium in the Nigerian NHIS is shared between the employees (deducted from the monthly pay) and the employers. The enrollees are however expected to pay 10% of their total bills on accessing care at the point of service. The NHIS in Nigeria is still in its infancy, and studies of its impacts on the health of the population have been largely restricted to acceptability and sustainability, while its impact on medication therapy problems such as MA and patients' clinical outcomes has remained largely unexplored ([@bibr13-2374373517732384],[@bibr14-2374373517732384]). The MA traditionally has been determined using pill counts and self-reported questionnaires. The use of a standardized self-reported questionnaire has however gained a wider acceptance among researchers in comparison to other methods due to its low cost and time expenditure ([@bibr15-2374373517732384]). The Morisky MA-8 scale (MMA-8) is a standardized self-reported scale, which has been widely used by many researchers and acknowledged for its high reliability and validity in MA measurement ([@bibr15-2374373517732384] [@bibr16-2374373517732384]--[@bibr17-2374373517732384]).

Nigeria is presently witnessing a high morbidity and mortality among type 2 diabetics, with estimated 4 million people living with the disease ([@bibr18-2374373517732384]). The clinical outcome in diabetes care is known to be largely dependent on patients' MA ([@bibr19-2374373517732384]), and the effect of any health policy on MA should, therefore, be of a great concern to the stakeholders. Presently, less than 20% of the diabetics in Nigeria are covered by the NHIS ([@bibr20-2374373517732384]). The MA is a public health issue, and in view of the little reports from the low- and middle-income countries and the conflicting reports from the developed world of the influence of health insurance on MA, there is the need for a further study. This study aims to evaluate the influence of the NHIS on MA among diabetic patients in Southwest Nigeria.

Method {#section2-2374373517732384}
======

This study was cross-sectional, involving 110 consecutively selected type 2 insured and uninsured diabetic patients, who attended the outpatient diabetes clinics of the State Hospital Ijebu-Ode and Jericho Nursing Home, Ibadan, between May and September 2015. The 2 secondary health-care facilities are situated in the southwest, Nigeria. The clinics had no diabetologist at the time of the study but were manned by physicians who had been trained in diabetes care. The hospitals had 169 (insured = 61; uninsured = 108) registered diabetics at the time of the study. A sample size of 118 was considered adequate by the statistician. One hundred forty-six type 2 diabetics who met the study inclusion criteria were approached for participation in the study. The inclusion criteria were (1) being a type 2 diabetic patient, (2) being on oral antidiabetic agents, and (3) had at least 4 diabetes clinic visits prior to the time of the study. Exclusion criteria were (1) nonconsenting type 2 diabetic patients, (2) those transferred to another level of care, (3) those who were unable to answer the questionnaire, based on vision and hearing problems, and (4) inappropriately filled or unreturned questionnaire. A total of 120 copies of a questionnaire which took about 10 minutes to complete was administered to the participants while waiting for the consultation with the physicians. The diabetes clinics held twice in a week in the hospitals. The study was approved by the Olabisi Onabanjo University Teaching Hospital Health Research Ethics Committee (OOUTH/HREC/3/007) and the Ethics Review Committee of Ogun State Ministry of Health. The hospitals' authorities also gave approval for the study. The study was a part of the research evaluating the impacts of Nigerian NHIS on the quality of care and patients' clinical outcomes. Data were analyzed using Statistical Package for Social Sciences (SPSS version 18). *P* values \< .05 were considered significant

Evaluation of Patients' Perceptions of Cost and Pharmaceutical Care Services {#section3-2374373517732384}
----------------------------------------------------------------------------

A pretested 25-item questionnaire which was sectioned into 3 parts was used. Seven questions assessed the patients' socioeconomic demographics, 6 questions evaluated patients' perceptions of the effects of cost on oral antidiabetic drugs (OADs) accessibility, while 12 questions assessed patients' perceptions of selected pharmaceutical care (PC) services using a 5-point Likert scale "never to very often." Based on the response received, the scale was compressed to 3 with the option "never" removed and "very often" and "often" merged and recoded "always" in the result presentation. The questionnaire was validated by an academic and 2 clinical pharmacists. The participants' responses were tagged and coded to match the identity on their medical records. Descriptive statistics were used to present the sociodemographic parameters. The differences in patients' perceptions of care were analyzed using Pearson χ^2^ test.

Medication Adherence {#section4-2374373517732384}
--------------------

The MMA-8 questionnaire was used to assess MA. The MMA-8 categorizes MA based on the summated score of the patient responses to the adherence questions. High and medium adherences were considered adequate in this study. The association between patients' monthly payments for OADs and MA was analyzed using Pearson χ^2^ test.

Oral Antidiabetes Drug Utilization and Patients' Clinical Outcomes {#section5-2374373517732384}
------------------------------------------------------------------

The medical records of the participants were retrieved immediately after consultation with the physicians and cross matched with the code on the questionnaire. Information such as patients' sociodemography, comorbidities, number and names of OADs on the prescription, fasting blood glucose (FBG) on diagnosis, last FBG, year of diagnosis, duration on the insurance plan, among others, were extracted and evaluated. The blood glucose control was defined as the last FBG below 110 mg/dL (6.1 mmol/L). The mean number of drugs per prescription was determined. The differences in means of drugs per prescription and last FBG for both the insured and the uninsured were analyzed using *t* test. The relationship between the number of drugs prescribed and MA was determined using the χ^2^ test.

Results {#section6-2374373517732384}
=======

Selection of Study Participants {#section7-2374373517732384}
-------------------------------

Of 146 diabetic patients who met the inclusion criteria, 26 (17.8%) were excluded: 7 due to referral to a higher level of care, 5 due to impairments, and 14 refused to give consent, leaving only 120 patients who were administered the questionnaire. Only 110 (91.7%) of the 120 questionnaires distributed were eventually analyzed. The remaining was either not properly filled (6) or not returned (4). The valid respondents were subsequently used in other stages of the study.

Socioeconomic Demographics of the Respondents {#section8-2374373517732384}
---------------------------------------------

The majority of the respondents (68 \[61.8%\]) were uninsured, 75 (68.2%) earned below ~~N~~50 000 monthly, and 39 (35.5%) aged 60 years and above ([Table 1](#table1-2374373517732384){ref-type="table"}).

###### 

Socioeconomic Demographics of the Respondents.^a^

![](10.1177_2374373517732384-table1)

  Variables                  Insured, n (%)   Uninsured, n (%)   *P* Value
  -------------------------- ---------------- ------------------ -----------
  Gender                                                         
   Male                      21 (50.0%)       33 (48.5%)         .538
   Female                    21 (50.0%)       35 (51.5%)         
  Age, years                                                     
   30-39                     2 (4.8%)         8 (11.8%)          
   40-49                     16 (38.1%)       8 (11.8%)          .001
   50-59                     19 (45.2%)       18 (26.5%)         
   60 and above              5 (11.9%)        34 (50.0%)         
  Marital status                                                 
   Single                    8 (19.0%)        20 (29.4%)         
   Married                   34 (81.0%)       48 (70.6%)         .017
  Education qualification                                        
   No schooling              5 (11.9%)        12 (17.6%)         
   Primary                   2 (4.8%)         21 (30.9%)         
   Secondary                 11 (26.2%)       15 (22.1%)         .006
   Post-secondary            24 (57.1%)       20 (29.4%)         
  Monthly income                                                 
   Below ~~N~~20 000         4 (9.5%)         19 (27.9%)         
   ~~N~~20 000-~~N~~29 000   3 (7.1%)         24 (35.3%)         
   ~~N~~30 000-~~N~~39 000   7 (16.7%)        5 (7.4%)           .001
   ~~N~~40 000-~~N~~49 000   7 (16.7%)        6 (8.8%)           
   ~~N~~50 000               21 (50.0%)       14 (20.6%)         

^a^n indicates the number of participants and % indicates the percentage of frequency.

The majority of the uninsured respondents (51 \[75.0%\] of 68) were self-financed; (28) (66.7%) of 42 insured respondents were primary beneficiaries in the NHIS; and (29) (69.0%) of 42 of the insured had been on NHIS for greater than 5 years. The medical chart review showed that many of the participants (41 \[60.3%\] of 68) uninsured and 16 (38.1%) of 42 insured had been on OADs for more than 5 years; 22 (52.4%) of 42 insured and 47 (60.3%) of 68 uninsured had the last FBG above 6.1 mmol/L, with no significant difference between the groups (*P* = .673)

Respondents' Perceptions of the Effect of Cost of OAD {#section9-2374373517732384}
-----------------------------------------------------

Only 14 (12.8%) of the 101 respondents who knew their monthly cost of OADS claimed to spend less than ~~N~~1000 (equivalent \<\$3). There was a significant difference in the monthly cost of OADs (*P* = .0001) between the insured and the uninsured patients. The monthly cost of OADs is as shown in [Table 2](#table2-2374373517732384){ref-type="table"}

###### 

The Monthly Cost of Oral Antidiabetic Drugs Among the Participants.^a^

![](10.1177_2374373517732384-table2)

  Cost of Medication (\$ Equivalents)^b^   Insured, n (%)   Uninsured, n (%)   *P* Value
  ---------------------------------------- ---------------- ------------------ -----------
  Below ~~N~~1000 (\< \$3)                 9 (21.4%)        5 (7.4%)           
  ~~N~~1000-~~N~~1999 (\$6)                18 (42.9%)       15 (22.1%)         
  ~~N~~2000-~~N~~2999 (\$9)                5 (11.9%)        21 (30.9%)         .0001
  ~~N~~3000 and above (\>\$9)              9 (21.4%)        19 (27.9%)         
  I don't know                             1 (2.4%)         8 (11.8%)          

^a^n indicates the number of respondents and % indicates the percentage of frequency.

^b^Calculated at ~~N~~350 per dollar.

The majority of (27 \[64.3%\] of 42) the insured respondents have had to miss their drugs due to inability to pay for the OADs. The uninsured respondents (39 \[57.4%; *P* = .062\] of 68) perceived drug stock out; the insured respondents (21 \[50.0%; *P* = .046\] of 42) perceived long waiting time as a major factor contributing to their nonpurchase of OADS in the facilities.

Patients' Perceptions of PC {#section10-2374373517732384}
---------------------------

Fifty-eight (53.7%) of the 108 respondents who answered questions on the adequacy of counseling time considered the time adequate always; 92 (85.2%) of 108 claimed that the pharmacists emphasized the importance of MA always ([Table 3](#table3-2374373517732384){ref-type="table"}).

###### 

Respondents Opinion About Some Pharmaceutical Care Activities Offered by Pharmacists.^a^

![](10.1177_2374373517732384-table3)

  Pharmaceutical Care Activities                                      Frequency of Services                                                                                                
  ------------------------------------------------------------------- -------------------------------------- ----------------------- ---------------------- ---------------------- ------- ---------
  Willingness to answer patients' questions (N = 110)                 Uninsured (n = 68); insured (n = 42)   57 (83.8); 38 (90.5)    8 (11.8); 4 (9.5)      3 (4.4); 0 (0%)        2.11    .349
  Counseling on medication (N = 102)                                  Uninsured (n = 65); insured (n = 37)   39 (60.0); 16 (43.2)    21 (32.3); 18 (48.6)   5 (7.7); 3 (8.1)       2.88    .237
  Adequacy of counseling time (N = 108)                               Uninsured (n = 67); insured (n = 41)   38 (56.7%); 20 (48.8)   12 (17.9); 20 (48.8)   17 (25.4); 1 (2.4)     16.51   \<.0005
  Enquiry about adherence to nonpharmacological treatment (N = 105)   Uninsured (n = 66); insured (n = 39)   6 (9.1); 11 (28.2)      12 (18.2); 12 (30.8)   48 (72.7); 16 (41.0)   11.27   .004
  Enquiry about the last laboratory investigation (N = 100)           Uninsured (n = 62); insured (n = 38)   6 (9.7); 2 (5.3)        7 (11.3); 6 (15.8)     49 (79.0); 30 (78.9)   2.54    .281
  Education of family members about diabetes (N = 104)                Uninsured (n = 63); insured (n = 41)   10 (15.9); 6 (14.6)     14 (22.2); 5 (12.2)    39 (61.9); 30 (73.1)   1.87    .393
  Explanation of therapeutic goal to the patient (N = 108)            Uninsured (n = 68); Insured (n = 40)   22 (32.4); 14 (35.0)    11 (16.2); 4 (10.0)    36 (52.9); 22 (55.0)   0.71    .700
  Emphasis on medication adherence (N = 108)                          Uninsured (n = 67); insured (n = 41)   56 (83.6); 36 (87.8)    7 (10.4); 4 (9.8)      4 (6.0); 1 (2.4)       0.75    .687
  Encouragement about self- monitoring of blood glucose (N = 108)     Uninsured (n = 67); insured (n = 41)   35 (52.2); 38 (92.7)    8 (11.9); 2 (4.9)      24 (35.8); 1 (2.4)     19.77   \<.0005
  Enquiry about patients' experience of OADs (N = 105)                Uninsured (n = 64); insured (n = 41)   31 (48.4); 23 (56.1)    16 (25.0); 16 (39.0)   17 (26.6); 2 (4.9)     8.39    .015
  Provision of dosage form (N = 106)                                  Uninsured (n = 65); insured (n = 41)   61 (93.8); 40 (97.6)    4 (6.2); 1 (2.4)       0 (0.0); 0 (0.0)       0.77    .680

Abbreviation: OADs, oral antidiabetic drugs.

^a^n indicates the number of valid respondents and % indicates the percentage frequency calculated based on the number of valid respondents.

^b^χ^2^ *P* value for analysis of difference in opinions between insured and the uninsured. Only valid responses were considered for analysis.

Income and Cost of Medication versus MA {#section11-2374373517732384}
---------------------------------------

Respondents with monthly income below ~~N~~20 000 had lowest MA (*P* = .580). Only 12 (10.9%) respondents had high adherence on the MMA-8 scale ([Table 4](#table4-2374373517732384){ref-type="table"}).

###### 

Income, Cost of Medication, Insurance Status, and Medication Adherence.^a^

![](10.1177_2374373517732384-table4)

  Variables                          Medication Adherence   *P* Value^c^               
  ---------------------------------- ---------------------- -------------- ----------- -------
  Income^b^                                                                            .58
   \<~~N~~20 000 (\<60)              0 (0.0)                10 (43.5)      13 (56.5)   
   ~~N~~20 000-~~N~~29 000 (\<90)    0 (0.0)                12 (44.4)      15 (55.6)   
   ~~N~~30 000-~~N~~39 000 (\<120)   2 (16.7)               4 (33.3)       6 (50.0)    
   ~~N~~40 000-~~N~~49 000 (\<140)   2 (15.4)               5 (38.5)       6 (46.2)    
   ~~N~~50 000 and above (\>150)     5 (14.3)               13 (37.1)      17 (48.6)   
  Cost of medication, monthly                                                          .037
   \< ~~N~~1000(\<3)                 7 (50.0)               3 (21.4)       4 (28.6)    
   ~~N~~1000-~~N~~1999(6)            25 (75.8)              5 (15.2)       3 (9.1)     
   ~~N~~2000-~~N~~2999(9)            9 (34.6)               14 (53.8)      3 (11.5)    
   ~~N~~3000 and above (\>9)         2 (7.1)                12 (42.9)      14 (50.0)   
   I don't know                      0 (0.0)                5 (55.6)       4 (44.4)    
  Insurance status                                                                     .0002
   Insured                           9 (21.4)               22 (52.4)      11 (26.2)   
   Uninsured                         3 (4.4)                22 (32.4)      43 (63.2)   

^a^n indicates the number of respondents and % indicates the percentage frequency of valid respondents.

^b^Cost presented in Naira (\$ equivalent). Calculated at ~~N~~350 per dollar.

^c^χ^2^ value.

Age and educational qualification were not significantly associated with MA, *P* = .282 and *P* = .394, respectively. The majority (78 \[70.9%\] of 110) of the respondents had more than 4 drugs per prescriptions (mean ± SD; 5.138 ± 1.565, *P* = .067). Metformin accounted for 110 (50.2%) of the 219 OADs encounters, glibenclamide 97 (44.3%), and pioglitazone 12 (5.5%). The insured received 10 (83.3%) of the 12 pioglitazone prescriptions. The patients' monthly cost of OADs was significantly associated with MA (*P* = .037). The number of drugs prescribed and the last FBG were not significantly associated with MA (*P* = .092 and *P* = .594, respectively).

Discussion {#section12-2374373517732384}
==========

Previous studies on the influence of NHIS on MA in the developed countries reported conflicting results ([@bibr21-2374373517732384],[@bibr22-2374373517732384]). This study, however, showed that NHIS may influence MA. The insured in this study had significantly higher MA than their uninsured counterparts. The difference in the monthly cost of drugs between the insured and the uninsured patients may have contributed to the difference in the MA between the groups. This study finding indicates the necessity of scaling up NHIS to cover more type 2 diabetic patients in Nigeria. The MA in this study was, however, lower than previously reported in the country ([@bibr8-2374373517732384],[@bibr23-2374373517732384]). The different settings could have accounted for the observed differences. The earlier studies were carried out among patients attending tertiary health facilities, who could have had better medication information and treatments to aid their MA.

Although the insured patients pay just 10% of the drug bills, the majority claimed it contributed to their nonaccessibility of OADs. This finding contradicts the conclusion of a review on the impact of drug co-payment on drug utilization by patients ([@bibr10-2374373517732384]). This co-payment fees being paid by the insured patients can be a hindrance to achieving adequate MA among the patients. The policymakers will need to consider this observation in the review of the NHIS. A payment plan based on the individual income should be considered. This suggestion is based on the finding of the study that the effect of the cost of medication on MA may be more significant among diabetic patients with low monthly incomes.

The NHIS appears not to have influenced the availability of OADs in the health-care facilities. The majority of the insured patients claimed OADs were not sometimes available in the health-care facilities. Inability to access medications at the health-care facility has a potentially negative effect on MA, considering that some of the patients may be discouraged from honoring their future clinic appointments. The insured patients compared with the uninsured considered waiting time to be long in the facilities and this contributed to their inability to purchase OADs in the facilities. The bureaucratic processes involved in the documentation of NHIS patients' medication could have been responsible for this observation. Waiting time has been shown to have a potentially negative effect on patients' MA ([@bibr3-2374373517732384]).

The study observed a negative influence of the NHIS on the pharmacist--patient relationship. Pharmacists appeared to favor the uninsured patients with regard to the counselling time and the quality of medication information provided. This discriminatory practices may potentially erode the insured patients' trust in the pharmacists, which may consequently affect the patients' MA. Inadequate time for medication counseling can result in poor understanding of medication use by the patients, and this has been reported to be a major cause of medication nonadherence in patients ([@bibr4-2374373517732384]).

The association between the number of drugs and patients' MA has been inconsistent in the literature ([@bibr19-2374373517732384]). This study, however, did not find any significant association between the number of drugs prescribed and the MA, in contradiction of the report of an earlier study in the country ([@bibr23-2374373517732384]). There was no difference in the number of drugs prescribed to both the insured and the uninsured patients in this study, which may indicate that the NHIS did not negatively influence the prescribing habits of the physicians. This study, however, took note that the insured patients received a more expensive and more toxic drug, pioglitazone than the uninsured. This observation is of concern, especially when there was no indication for its use in the patients' medical records. Prescription of expensive drugs may potentially reduce patients' MA through an increase in the expenses on medication. The side effects of pioglitazone may also contribute to medication nonadherence in the patients ([@bibr3-2374373517732384],[@bibr24-2374373517732384]).

The blood glucose control in the patients was not significantly associated with both the patients' insurance status and MA. This supports the conclusion of the report of a similar study in Nigeria that MA alone may not account for blood glucose control in type 2 diabetes ([@bibr25-2374373517732384]).

The use of only public health facilities is a limitation in the study since there are many NHIS accredited private health-care facilities offering diabetic care in the country. The use of a self-report tool (MMA-8) is subject to recall bias and patients tend to overestimate their adherence. These limitations should, therefore, be considered in the generalization of the results.

Conclusion {#section13-2374373517732384}
==========

The study concluded that the NHIS may influence patients' MA. There was a difference in MA between the insured and the uninsured diabetic patients. This difference in MA could be due to the difference in the monthly cost of OADs between the groups. A nationwide study is needed for a further evaluation of the influence of the scheme on MA.
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